Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

187.52B

Market cap187.52B

Price-Earnings ratio

22.53

Price-Earnings ratio22.53

Dividend yield

2.07%

Dividend yield2.07%

Average volume

8.25M

Average volume8.25M

High today

$153.98

High today$153.98

Low today

$150.33

Low today$150.33

Open price

$152.25

Open price$152.25

Volume

7.36M

Volume7.36M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$93.37

52 Week low$93.37

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $151.68, giving the company a market capitalization of 187.52B. It carries a P/E multiple of 22.53 and pays a dividend yield of 2.1%.

On 2026-02-20, Gilead Sciences(GILD) stock moved within a range of $150.33 to $153.98. With shares now at $151.68, the stock is trading +0.9% above its intraday low and -1.5% below the session's peak.

Trading volume for Gilead Sciences(GILD) stock has reached 7.36M, versus its average volume of 8.25M.

The stock's 52-week range extends from a low of $93.37 to a high of $157.29.

GILD News

TipRanks 2d

Gilead price target raised to $175 from $155 at UBS

UBS raised the firm’s price target on Gilead (GILD) to $175 from $155 and keeps a Buy rating on the shares. Gilead will present Phase I Q6M pharmacokinetic data...

Simply Wall St 3d

Gilead Sciences Data And Label Updates Test HIV And CAR T Valuation

Gilead Sciences and Kite are highlighting new late stage HIV and CAR T cell therapy data, along with regulatory updates, at upcoming medical meetings in 2026....

Simply Wall St 5d

Did Gilead’s Strong Quarter, Bigger Dividend and Yescarta Win Just Redefine Its Story?

In February 2026, Gilead Sciences reported higher fourth-quarter and full-year 2025 revenue and earnings, raised its quarterly dividend to US$0.82 per share, co...

Analyst ratings

71%

of 31 ratings

Buy

71%

Hold

22.6%

Sell

6.5%

More GILD News

Simply Wall St 6d

Gilead Sciences Valuation Check As Strong Results Yeztugo Uptake And Yescarta Expansion Draw Attention

Gilead Sciences (GILD) is back in focus after a busy stretch, including strong Q4 and 2025 results, rapid take up of HIV prevention drug Yeztugo, and an FDA lab...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.